NGM Biopharmaceuticals - NGM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.55
  • Forecasted Upside: 0.65%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.54
▼ -0.02 (-1.28%)
Get New NGM Biopharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NGM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NGM

Analyst Price Target is $1.55
▲ +0.65% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for NGM Biopharmaceuticals in the last 3 months. The average price target is $1.55, with a high forecast of $1.55 and a low forecast of $1.55. The average price target represents a 0.65% upside from the last price of $1.54.

This chart shows the closing price for NGM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in NGM Biopharmaceuticals. This rating has held steady since February 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/17/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/15/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/12/2024Raymond JamesDowngradeOutperform ➝ Market Perform
2/28/2024B. RileyDowngradeBuy ➝ Neutral
2/28/2024TD CowenReiterated RatingOutperform ➝ Market Perform$4.00 ➝ $1.55
2/27/2024CitigroupReiterated RatingBuy ➝ Neutral
11/22/2023B. RileyLower TargetBuy ➝ Buy$7.00 ➝ $3.50
5/3/2023CitigroupInitiated CoverageBuy$6.00
3/30/2023B. RileyLower TargetBuy$8.00 ➝ $7.00
10/20/2022Piper SandlerLower Target$4.00
10/18/2022CowenLower TargetOutperform$32.00 ➝ $9.00
10/18/2022CowenLower TargetOutperform$32.00 ➝ $9.00
10/17/2022Raymond JamesDowngradeStrong-Buy ➝ Outperform$42.00 ➝ $4.00
10/17/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$29.00 ➝ $4.00
10/17/2022B. RileyLower Target$29.00 ➝ $8.00
10/17/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
10/17/2022Piper SandlerDowngradeOverweight ➝ Neutral
10/7/2022B. RileyLower TargetBuy$35.00 ➝ $29.00
7/20/2022Jefferies Financial GroupInitiated CoverageBuy$25.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$34.00 ➝ $29.00
3/2/2022Raymond JamesDowngradeStrong-Buy ➝ Outperform
1/7/2022Piper SandlerBoost Target$30.00 ➝ $32.00
11/5/2021Raymond JamesBoost TargetStrong-Buy$39.00 ➝ $42.00
9/16/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$29.00 ➝ $35.00
9/13/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$27.00 ➝ $39.00
9/7/2021B. RileyBoost TargetBuy$32.00 ➝ $35.00
8/9/2021CowenBoost TargetOutperform$20.00 ➝ $32.00
8/9/2021BMO Capital MarketsBoost TargetOutperform$20.00 ➝ $29.00
8/6/2021Raymond JamesBoost TargetOutperform$22.00 ➝ $27.00
8/6/2021Piper SandlerBoost TargetPositive ➝ Overweight$20.00 ➝ $30.00
5/24/2021Stifel NicolausLower TargetBuy$43.00 ➝ $22.00
5/24/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$52.00 ➝ $22.00
3/5/2021Raymond JamesBoost TargetStrong-Buy$50.00 ➝ $52.00
3/5/2021Chardan CapitalBoost TargetBuy$39.00 ➝ $44.00
2/9/2021The Goldman Sachs GroupBoost TargetBuy$28.00 ➝ $38.00
1/8/2021Raymond JamesBoost TargetStrong-Buy$32.00 ➝ $50.00
1/5/2021Stifel NicolausReiterated RatingTop Pick
12/21/2020Smith Barney CitigroupBoost Target$28.00 ➝ $44.00
12/14/2020B. RileyBoost TargetBuy$30.00 ➝ $38.00
10/20/2020Chardan CapitalReiterated RatingBuy$39.00
8/14/2020B. RileyReiterated RatingBuy$30.00
8/13/2020Chardan CapitalLower TargetBuy$40.00 ➝ $39.00
7/30/2020Piper SandlerInitiated CoverageOverweight$30.00
7/7/2020Chardan CapitalInitiated CoverageBuy$40.00
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$30.00
5/21/2020B. RileyReiterated RatingBuy$30.00
5/18/2020Stifel NicolausReiterated RatingBuy$32.00
5/14/2020Raymond JamesBoost TargetStrong-Buy$31.00 ➝ $32.00
4/19/2020Raymond JamesInitiated CoverageStrong-Buy$31.00
4/6/2020Raymond JamesInitiated CoverageStrong-Buy$31.00
3/27/2020CitigroupLower TargetBuy$34.00 ➝ $28.00
3/23/2020CowenReiterated RatingBuy$30.00
3/19/2020Stifel NicolausLower TargetBuy$33.00 ➝ $32.00
3/19/2020B. RileyReiterated RatingBuy$30.00
2/26/2020B. RileyBoost Target$24.00 ➝ $30.00
2/25/2020Stifel NicolausBoost TargetBuy$26.00 ➝ $33.00
2/25/2020CitigroupBoost TargetPositive ➝ Buy$31.00 ➝ $34.00
2/24/2020B. RileyReiterated RatingBuy$24.00 ➝ $24.00
2/24/2020CowenReiterated RatingBuy
2/11/2020B. RileyReiterated RatingBuy$24.00
12/10/2019CitigroupReiterated RatingBuy$31.00
(Data available from 12/8/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NGM Biopharmaceuticals logo
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.54
Low: $1.54
High: $1.57

50 Day Range

MA: $1.55
Low: $1.52
High: $1.63

52 Week Range

Now: $1.54
Low: $0.60
High: $4.69

Volume

2,390,800 shs

Average Volume

1,467,160 shs

Market Capitalization

$128.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of NGM Biopharmaceuticals?

The following Wall Street research analysts have issued stock ratings on NGM Biopharmaceuticals in the last twelve months: B. Riley, Citigroup Inc., Raymond James, and TD Cowen.
View the latest analyst ratings for NGM.

What is the current price target for NGM Biopharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for NGM Biopharmaceuticals in the last year. Their average twelve-month price target is $1.55, suggesting a possible upside of 0.6%. TD Cowen has the highest price target set, predicting NGM will reach $1.55 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $1.55 for NGM Biopharmaceuticals in the next year.
View the latest price targets for NGM.

What is the current consensus analyst rating for NGM Biopharmaceuticals?

NGM Biopharmaceuticals currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NGM, but not buy more shares or sell existing shares.
View the latest ratings for NGM.

What other companies compete with NGM Biopharmaceuticals?

How do I contact NGM Biopharmaceuticals' investor relations team?

NGM Biopharmaceuticals' physical mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 243-5555 and its investor relations email address is [email protected]. The official website for NGM Biopharmaceuticals is www.ngmbio.com. Learn More about contacing NGM Biopharmaceuticals investor relations.